PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsactinic keratosis
MeSH D055623 - actinic keratosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D011230:Precancerous conditions
0 Companies
0 Drugs
Success rate
D007642:Keratosis
$
Success rate
D055623: 
Actinic keratosis
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
PadagisImiquimod Imiquimod  2010-09-07   
Ingenol mebutate Ingenol Mebutate  2019-01-07   
Taro PharmaceuticalImiquimod Imiquimod  2011-04-15   
Glenmark PharmaceuticalsImiquimod Imiquimod  2012-03-06   
LEO PharmaIngenol mebutate Picato 2026-12-18 2012-01-23   
AlmirallTirbanibulin Klisyri  2021-07-16   
3MImiquimod Zartra  1998-09-18   
Bausch Health CompaniesImiquimod Aldara 2024-04-01 1997-02-27   
Imiquimod Zyclara 2029-08-18 2010-03-25   
Cosette Pharmaceuticals Imiquimod Imiquimod  2011-04-18   
ApotexImiquimod Imiquimod  2012-04-06   
Strides Pharma GlobalImiquimod Imiquimod  2014-06-24   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
83%
15/18
Phase 2
30%
7/23
Phase 3
83%
15/18
Approved: 7Overall Success rate: 21%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Padagis
LEO Pharma
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use